On July 15, PegBio Pharma-B rose 8.78% in regular trading, trading at HK$6.64/share, with turnover of HK$75.66 million. The rebound follows the prior session's approximately 8% decline driven by profit-taking.

The underlying catalyst remains the company's memorandum of understanding signed on July 8 with Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for PegBio's obesity and metabolic disease candidates, while exploring R&D, manufacturing, and commercialization cooperation outside China.

The stock had surged approximately 29% on July 10 when the MoU was first announced, gained over 4% on July 13, then pulled back roughly 8% on July 14 as short-term profit-taking intensified. Today's movement represents a technical recovery following that correction, with the collaboration narrative continuing to support sentiment despite the agreement remaining at an early screening stage with no formal binding development commitments yet in place.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)